Management of chronic thromboembolic pulmonary hypertension (CTEPH) includes multimodal therapy that depends on expert centres' experience.1,2 Guidelines advocate for pulmonary endarterectomy (PEA) to ...

Cardiovascular health is affected by environmental pollution, including microplastics and nanoplastics that have entered the food chain.

Chronic thromboembolic pulmonary hypertension (CTEPH) is the clinical term for high blood pressure in the lungs caused by blockages, such as clots, in the blood vessels. Although CTEPH therapies ...

Conclusion: The surgical treatment of choice is pneumonectomy with contralateral pulmonary endarterectomy. Oncological vigilance regarding angiosarcoma in occlusive-stenotic lesions of the pulmonary ...

Gradient Denervation Technologies is a Paris-based medical device company developing a minimally invasive, ultrasound-based device for the treatment of pulmonary hypertension.

Shares of Insmed jumped Tuesday after the biopharmaceutical firm reported positive results from a Phase 2 trial for its treatment of pulmonary arterial hypertension.

Panelists discuss how pulmonary arterial hypertension diagnosis requires comprehensive evaluation including right heart catheterization to confirm hemodynamic criteria, with normal mean PA ...

Pulmonary arterial hypertension (PAH) represents a complex disease with multifaceted pathophysiology involving over 20 identified genetic mutations that can contribute to disease development.

Pulmonary artery denervation has become a promising therapeutic intervention in the management of pulmonary hypertension. While our findings suggest a substantial role for PADN in treatment ...

Sotatercept improves exercise capacity and delays the time to clinical worsening in patients with World Health Organization (WHO) functional class II or III pulmonary arterial hypertension. The eff ...